A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 12-WEEK STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF ORAL DIFELIKEFALIN IN SUBJECTS WITH ADVANCED CHRONIC KIDNEY DISEASE AND MODERATE-TO-SEVERE PRURITUS WITH A 24-WEEK OPEN-LABEL EXTENSION

Registry ID
CR845-110210
Source registry
HEALTH_CANADA
Status
Closed
Study type
INTERVENTIONAL
Sponsor
CARA THERAPEUTICS
Start date
2024-01-09
Completion date
2024-02-23
Last update
2023-09-13

Conditions

Related clinical trials

View on source registry